Rationale and design of a randomized clinical trial of ?-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - 15/08/11
, Harry C. Dietz, MD b, Lisa M. Wruck, PhD c, Timothy J. Bradley, MD d, Steven D. Colan, MD a, c, Richard B. Devereux, MD e, Gloria L. Klein, MS c, Jennifer S. Li, MD f, L. LuAnn Minich, MD g, Stephen M. Paridon, MD h, Gail D. Pearson, MD, ScD i, Beth F. Printz, MD j, Reed E. Pyeritz, MD, PhD k, Elizabeth Radojewski, RN d, Mary J. Roman, MD e, J. Philip Saul, MD l, Mario P. Stylianou, PhD i, Lynn Mahony, MD, mfor the Pediatric Heart Network Investigators
Résumé |
Background |
Cardiovascular disease, including aortic root dilation, dissection, and rupture, is the leading cause of mortality in patients with Marfan syndrome (MFS). The maximal aortic root diameter at the sinuses of Valsalva is considered the best predictor of adverse cardiovascular outcome. Although advances in therapy have improved life expectancy, affected individuals continue to suffer cardiovascular morbidity and mortality. Recent studies in an FBN1-targeted mouse model of MFS with aortic disease similar to that seen in humans showed that treatment with losartan normalized aortic root growth and aortic wall architecture.
Methods |
The Pediatric Heart Network designed a randomized clinical trial to compare aortic root growth and other short-term cardiovascular outcomes in subjects with MFS receiving atenolol or losartan. Individuals 6 months to 25 years of age with a body surface area–adjusted aortic root z score >3.0 will be eligible for inclusion. The primary aim is to compare the effect of atenolol therapy with that of losartan therapy on the rate of aortic root growth over 3 years. Secondary end points include progression of aortic regurgitation; incidence of aortic dissection, aortic root surgery, and death; progression of mitral regurgitation; left ventricular size and function; echocardiographically derived measures of central aortic stiffness; skeletal and somatic growth; and incidence of adverse drug reactions.
Conclusion |
This randomized trial should make a substantial contribution to the management of individuals with MFS and expand our understanding of the mechanisms responsible for the aortic manifestations of this disorder.
Le texte complet de cet article est disponible en PDF.Plan
| This work was supported by U01 HL068285 (Lacro); U01 HL068270 (Wruck, Mahony, Colan, Klein), U01 HL068269 (Li), U01 HL068292 (Minich), U01 HL068290 (Printz, Devereux, Roman), U01 HL068288 (Bradley), U01 HL068281 (Saul), and U01 HL068279 (Paridon, Pyeritz) from the National Heart, Lung, and Blood Institute (Bethesda, MD), the Howard Hughes Medical Institute (Baltimore, MD) (Dietz); the National Marfan Foundation (Port Washington, NY) (Dietz); and the Smilow Center for Marfan Syndrome Research (Baltimore, MD) (Dietz). |
Vol 154 - N° 4
P. 624-631 - octobre 2007 Retour au numéro
Article précédent
- Statin therapy in heart failure: Prognostic effects and potential mechanisms
- Jeffrey G. Shanes, Kira N. Minadeo, Ann Moret, Mordechai Groner, Sean A. Tabaie
- Rationale and design of the fractional flow reserve versus angiography for multivessel evaluation (FAME) study
- William F. Fearon, Pim A.L. Tonino, Bernard De Bruyne, Uwe Siebert, Nico H.J. Pijls, for the FAME Study Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?